Excessive Long-Term Platelet Inhibition with Prasugrel or Ticagrelor and Risk of Infection: Another Hidden Danger?

American Journal of Therapeutics

Volumn 22, Issue 2, 2015, Pages e22-e27

  Kipshidze, Nodar ^a   Platonova, Elizabeth ^a   DiNicolantonio, James J ^b   Kuliczkowski, Wiktor ^c   Serebruany, Victor L ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b Wegmans Pharmacy   (United States)

^c MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; PRASUGREL; RIVAROXABAN; TICAGRELOR; ADENOSINE; ANTITHROMBOCYTIC AGENT;

ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; ARTICLE; DRUG SAFETY; HUMAN; INFECTION; INFECTION RISK; NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); ANALOGS AND DERIVATIVES; ANIMAL; CHEMICALLY INDUCED; TIME;

ADENOSINE; ANIMALS; HUMANS; INFECTION; PLATELET AGGREGATION INHIBITORS; PRASUGREL HYDROCHLORIDE; TIME FACTORS;

EID: 84925256030     PISSN: 10752765     EISSN: 15363686     Source Type: Journal    
DOI: 10.1097/MJT.0b013e3182a4ef6f     Document Type: Article

References (25)

1. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494-502.
2. Steinhubl SR, Berger PB, Mann JT III, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;288:2411-2420.
3. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:2001-2015.
4. COMMIT Collaborative Group. Addition of clopidogrel to aspirin in 45852 patients with acute myocardial infarction: randomized placebo-controlled trial. Lancet. 2005;366:1607-1621.
5. Wallentin L, Becker RC, Budaj A, et al The PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045-1057.
6. Mehta SR, Tanguay JF, Eikelboom JW, et al. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet. 2010;376:1233-1243.
7. Serebruany VL. Prasugrel and cancer risks: potential causes and implications. Am J Med. 2009;122:407-408.
8. Gross AK, Dunn SP, Feola DJ, et al. Clopidogrel treatment and the incidence and severity of community acquired pneumonia in a cohort study and meta-analysis of antiplatelet therapy in pneumonia and critical illness. J Thromb Thrombolysis. 2013;35:147-154.
9. Blasco-Colmenares E, Perl TM, Guallar E, et al. Aspirin plus clopidogrel and risk of infection after coronary artery bypass surgery. Arch Intern Med. 2009;169:788-796.
10. Welsh RC, Rao SV, Zeymer U, et al INNOVATE-PCI Investigators. A randomized, double-blind, active-controlled phase 2 trial to evaluate a novel selective and reversible intravenous and oral P2Y12 inhibitor elinogrel versus clopidogrel in patients undergoing nonurgent percutaneous coronary intervention: the INNOVATE-PCI trial. Circ Cardiovasc Interv. 2012;5:336-346.
11. Cannon CP, Husted S, Harrington RA, et al. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial. J Am Coll Cardiol. 2007;50:1844-1851.
12. Ramsdale DR, Aziz S, Newall N, et al. Bacteremia following complex percutaneous coronary intervention. J Invasive Cardiol. 2004;16:632-634.
13. Nelson MT, Greenblatt DY, Soma G, et al. Preoperative factors predict mortality after major lower-extremity amputation. Surgery. 2012;152:685-694.
14. Seidel M, Winning J, Claus RA, et al. Beneficial effect of clopidogrel in a mouse model of polymicrobial sepsis. J Thromb Haemost. 2009;7:1030-1032.
15. Winning J, Reichel J, Eisenhut Y, et al. Anti-platelet drugs and outcome in severe infection: clinical impact and underlying mechanisms. Platelets. 2009;20:50-57.
16. Margetic S. Inflammation and haemostasis. Biochem Med (Zagreb). 2012;22:49-62.
17. Tsoumani ME, Kalantzi KI, Goudevenos IA, et al. Platelet-mediated inflammation in cardiovascular disease. Potential role of platelet-endothelium interactions. Curr Vasc Pharmacol. 2012;10:539-549.
18. Prasugrel secondary review. Available at: http://www.fda.gov/ohrms/dockets/ac/09briefing/2009-4412b1-00-FDA.htm. Assessed January 9, 2013.
19. The FDA ticagrelor review of complete response. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/nda/2011/022433Orig1s000TOC.cfm. Assessed January 9, 2013.
20. Varenhorst C, Alström U, Scirica BM, et al. Factors contributing to the lower mortality with ticagrelor compared with clopidogrel in patients undergoing coronary artery bypass surgery. J Am Coll Cardiol. 2012;60:1623-1630.
21. Prasugrel prescription insert. Eli Lilly, Indianapolis, IN. Table 4, p.8. 2009.
22. Spiel AO, Derhaschnig U, Schwameis M, et al. Effects of prasugrel on platelet inhibition during systemic endotoxaemia: a randomized controlled trial. Clin Sci (Lond). 2012;123:591-600.
23. Totani L, Dell'Elba G, Martelli N, et al. Prasugrel inhibits platelet-leukocyte interaction and reduces inflammatory markers in a model of endotoxic shock in the mouse. Thromb Haemost. 2012;107:1130-1140.
24. Roe MT, Armstrong PW, Fox KA, et al. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med. 2012;367:1297-1309.
25. Mega JL, Braunwald E, Wiviott SD, et al; ATLAS ACS 2-TIMI 51 Investigators. Rivaroxaban in patientswith a recent acute coronary syndrome. N Engl J Med. 2012;366:9-19.